(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 December 2022 (29.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/271867 A1

(51) International Patent Classification:
A61K 38/26 (2006.01) *A61P 3/06* (2006.01)
C07K 16/18 (2006.01) *A61P 3/10* (2006.01)
C07K 16/24 (2006.01) *A61P 21/06* (2006.01)
A61P 3/04 (2006.01)

(21) International Application Number:
PCT/US2022/034588

(22) International Filing Date:
22 June 2022 (22.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/214,234	23 June 2021 (23.06.2021)	US
63/260,136	10 August 2021 (10.08.2021)	US
63/260,254	13 August 2021 (13.08.2021)	US
63/266,348	03 January 2022 (03.01.2022)	US
63/269,702	21 March 2022 (21.03.2022)	US

(71) Applicant: **SCHOLAR ROCK, INC.** [US/US]; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **LONG, Kimberly**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **CHYUNG, Yung**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **NOMIKOS, George**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **FLIER, Jeffrey S.**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **WEBSTER, Micah T.**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **CHAPRON, Christopher**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(74) Agent: **JACOBSTEIN, Jeffrey M.**; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001-4413 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2022/271867 A1

(54) Title: A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS

(57) Abstract: The present disclosure relates to the treatment of metabolic disorders, such as metabolic syndrome, obesity, and type 2 diabetes. Adjunct therapies and combination therapies that include a myostatin pathway inhibitor, used in conjunction with a GLP-1 pathway activator are disclosed.